Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 14.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 16,055 shares of the company’s stock after selling 2,795 shares during the period. Janney Montgomery Scott LLC’s holdings in Tarsus Pharmaceuticals were worth $825,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $44,000. Quarry LP purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $166,000. HighTower Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $207,000. Finally, Summit Investment Advisors Inc. increased its position in shares of Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after acquiring an additional 244 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $40.51 on Tuesday. The company has a market capitalization of $1.70 billion, a PE ratio of -14.84 and a beta of 0.83. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. The company’s fifty day moving average price is $44.08 and its 200 day moving average price is $47.78. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. The firm had revenue of $78.34 million for the quarter, compared to analysts’ expectations of $72.50 million. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TARS shares. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a research note on Monday, May 5th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They set an “outperform” rating and a $75.00 target price for the company. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.